# Teclistamab-Daratumumab in AL Amyloidosis

> **NCT07110844** · PHASE2 · RECRUITING · sponsor: **Suzanne Lentzsch, MD** · enrollment: 25 (estimated)

## Conditions studied

- Amyloid Light-chain Amyloidosis

## Interventions

- **DRUG:** Teclistamab
- **DRUG:** Daratumumab and Hyaluronidase-fihj

## Key facts

- **NCT ID:** NCT07110844
- **Lead sponsor:** Suzanne Lentzsch, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2031-10
- **Final completion:** 2033-10
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07110844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07110844, "Teclistamab-Daratumumab in AL Amyloidosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07110844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*